Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
MWN-AI** Summary
Virax Biolabs Group Limited (NASDAQ: VRAX) has achieved significant progress by obtaining ISO 13485:2016 and ISO 9001:2015 certifications for its quality management system through its subsidiary, Virax Biolabs (UK) Limited. Issued by LRQA, the certifications, which are valid until February 2029, bolster the company’s framework for developing regulated in vitro diagnostics (IVD) and support its U.S. clinical validation efforts.
The ISO 13485:2016 certification pertains to the design and development of immunological assay components and kits for IVD applications, while ISO 9001:2015 focuses on broader quality management aspects. These internationally recognized standards establish robust protocols for design control, risk management, supplier qualification, and manufacturing consistency. For Virax, they enhance operational controls and documentation processes, which are critical for advancing its diagnostic technology, particularly for post-acute infection syndromes (PAIS)—including Long COVID.
Virax’s ongoing partnership with Emory University's ADJUST Center is a crucial facet of its strategy, focusing on clinical studies of ViraxImmune™ to evaluate immune profiling in Long COVID patients. This collaboration aims to generate data that will inform regulatory planning and potential commercial routes.
Chairman and CEO James Foster highlighted the certifications as a meaningful milestone that underpins the company’s regulated development efforts and evidence generation through clinical programs in both the UK and the U.S. Furthermore, Virax is exploring U.S. testing services that may leverage a laboratory-developed test (LDT) pathway.
With these ISO certifications, Virax is laying a robust foundation for future growth, positioning itself strategically in the diagnostic landscape of viral diseases and immune responses. For more information, visit Virax Biolabs’ official website.
MWN-AI** Analysis
Virax Biolabs Group Limited (NASDAQ: VRAX) has made significant strides by obtaining ISO 13485:2016 and ISO 9001:2015 certifications, indicating a robust quality management system that is poised to enhance its regulatory compliance and development of in vitro diagnostics (IVDs). This achievement establishes a critical foundation for the company’s strategy surrounding post-acute infection syndromes (PAIS), including Long COVID, and supports its ongoing U.S. clinical validation initiatives.
The certifications, awarded by LRQA, are vital in assuring stakeholders—including investors—that Virax is committed to maintaining high standards in the design, development, and manufacturing of its diagnostic technologies. The rigorous process of obtaining these ISO designations highlights the company's capability to navigate the highly regulated environment of medical diagnostics, which may enhance investor confidence and interest in the stock.
Given the growing attention on chronic post-viral syndromes, Virax seems well-positioned to capitalize on this market demand. The firm’s collaboration with Emory University for clinical studies on its ViraxImmune™ platform further underscores its commitment to producing clinically validated and commercially viable products. Investors should pay close attention to the outcomes of these studies, as they could lead to substantial market opportunities, particularly in the U.S. immunology sector.
As Virax also considers laboratory-developed tests (LDTs) as part of its expansion strategy, the potential for additional revenue streams could present favorable growth opportunities. With these ISO certifications reinforcing its operational framework and quality systems, investors may want to look for entry points in this promising biotech firm as it explores the evolving landscape of immune profiling and PAIS diagnostics.
In conclusion, the combination of regulatory achievements and strategic partnerships positions Virax favorably in the biotechnology market. This development warrants a cautious yet optimistic outlook for future investment opportunities, as the company embarks on a journey toward broader clinical validation and potential commercialization.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
LONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system. The certifications were issued by LRQA, with an issue date of 18 February 2026 and an expiry date of 17 February 2029.
Highlights:
- Virax believes the strengthened quality framework supports its post-acute infection syndromes ("PAIS") strategy by strengthening readiness for regulated in vitro diagnostic ("IVD") development and supporting U.S. clinical validation activities.
- Virax is also evaluating potential U.S. laboratory-based testing service offerings, which may include a laboratory-developed test ("LDT") pathway.
Within the scope of approval, ISO 13485:2016 covers the design and development of immunological assay components and kits, including antibody- and peptide-based reagents, for IVD applications. Within the scope of approval, ISO 9001:2015 covers the provision of manufacturing, design and development of Virax's research-use-only products and services.
ISO 13485 and ISO 9001 are internationally recognised quality management standards that establish a framework for design control, risk management, traceability, supplier qualification and manufacturing consistency. In simple terms, ISO 13485 is a widely used quality standard for medical devices and diagnostics, while ISO 9001 is a broader quality management standard used across many industries. Virax believes these certifications strengthen the controls and documentation needed to advance regulated diagnostics programmes and support clinical validation work.
Virax believes these certifications provide an important operational foundation for the Company's quality-managed development activities, including its in-development diagnostic technology for post-acute infection syndromes ("PAIS"), such as post-acute sequelae of SARS-CoV-2 ("PASC") (commonly referred to as "Long COVID"), and support the Company's broader strategy to build a T cell immune-profiling platform with a transatlantic clinical and regulatory footprint.
In parallel, Virax continues to advance its U.S. clinical validation work, which the Company believes is supported by a strengthened quality framework. As previously disclosed, Virax has entered into a Research Services Agreement ("RSA") with Emory University's ADJUST Center to conduct clinical studies of ViraxImmune™ focused on immune profiling in individuals with PASC (commonly referred to as "Long COVID"). Under the agreement, Emory will conduct laboratory testing and analysis to generate clinical data intended to inform Virax's regulatory planning and potential future commercial rollout.
Virax believes strengthening its quality systems is relevant to disciplined development and control of key assay components and supporting documentation processes, which can support validation activities and scale-up planning, subject to applicable regulatory requirements.
"Achieving ISO 13485 and ISO 9001 certification is a meaningful milestone for Virax," said James Foster, Chairman and Chief Executive Officer of Virax Biolabs. "It reflects the work our team has done to implement robust quality systems that support the regulated development of our immunological assays. This matters as we continue to execute our PAIS strategy, including strengthening the foundation for regulated IVD development and expanding our evidence base through UK and U.S. clinical programmes, while also evaluating potential U.S. laboratory-based testing pathways, which may include an LDT route."
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is developing T cell-based test technologies with the intention of providing an immunology profiling platform. T cell testing can be particularly effective in the diagnosis and therapeutics of post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
For more information, please visit www.viraxbiolabs.com
Caution Concerning Forward-Looking Statements
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms.
In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us.
These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Virax's Annual Report on Form 20-F for the year ended March 31, 2025. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
SOURCE Virax BioLabs Group Limited
FAQ**
How do the ISO 13485 and ISO 9001 certifications enhance the operational capabilities of Virax Biolabs Group Limited (VRAX) in terms of regulated IVD development and clinical validation activities?
What specific strategies is Virax Biolabs Group Limited (VRAX) employing to advance its post-acute infection syndromes (PAIS) program in conjunction with its recent ISO certifications?
In what ways does the collaboration with Emory University's ADJUST Center contribute to Virax Biolabs Group Limited (VRAX)'s goals for U.S. clinical validation and regulatory planning?
What are the potential impacts of Virax Biolabs Group Limited (VRAX) achieving ISO certification on its future product offerings, particularly regarding U.S. laboratory-developed tests (LDTs)?
**MWN-AI FAQ is based on asking OpenAI questions about Virax Biolabs Group Limited (NASDAQ: VRAX).
NASDAQ: VRAX
VRAX Trading
29.1% G/L:
$0.2165 Last:
223,250,768 Volume:
$0.24625 Open:
